BRIEF—Ubiquigent names Hozefa Amijee head of BD

UK-based Ubiquigent, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, has named Hozefa Amijee as head of business development (BD).

According to Ubiquigent, the appointment will further improve access to the company’s specialist contract research organization services and strengthen commercial partnerships, to meet the growing interest in the therapeutic potential of the DUB family of enzymes.

Dr Hozefa joins Ubiquigent from Cellesce where, as head of BD, he focused on growing partnerships and strategic alliances with top biotech and pharma companies, bringing the use of better patient-centric organoid models to drug discovery and development.